REVENUE (Tables)

3 Months Ended

Jun. 30, 2024

Disaggregation of Revenue [Line Items]

Financing Receivable, Allowance for Credit Loss [Table Text Block]

The rollforward for the allowance for credit losses for the six months ended June 30, 2024, was as follows:

	Accounts Receivable		Unbilled Services		Note and Other Receivables		Total
Balance as of December 31, 2023	$	32.7	$	7.5	$	0.7	$	40.9
Plus, credit loss expense	3.4		—		—		3.4
Less, write offs	2.0		5.7		—		7.7
Balance as of June 30, 2024	$	34.1	$	1.8	$	0.7	$	36.6

Contract with Customer, Asset and Liability [Table Text Block]

	June 30, 2024		December 31, 2023
Dx accounts receivable	$	1,331.4	$	1,135.2
BLS accounts receivable	791.6		810.8
Less BLS allowance for doubtful accounts	(34.1)		(32.7)
Accounts receivable	$	2,088.9	$	1,913.3
Gross unbilled services	$	159.3	$	192.9
Less reserve for unbilled services	(1.8)		(7.5)
Unbilled services	$	157.5	$	185.4
Unearned revenue	$	388.3	$	421.7

Disaggregation of Revenue [Table Text Block]

The Company's revenues by segment and by payers/customer groups for the three and six months ended June 30, 2024, and 2023, were as follows:

	For the Three Months Ended June 30, 2024								For the Three Months Ended June 30, 2023
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	24	%	—	%	—	%	24	%	24	%	—	%	—	%	24	%
Patients	10	%	—	%	—	%	10	%	10	%	—	%	—	%	10	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%
Third party	36	%	—	%	—	%	36	%	35	%	—	%	—	%	35	%
Total Dx revenues by payer	78	%	—	%	—	%	78	%	77	%	—	%	—	%	77	%
BLS
Pharmaceutical, biotechnology, and medical device companies	9	%	9	%	4	%	22	%	10	%	9	%	4	%	23	%
Total revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%

	For the Six Months Ended June 30, 2024								For the Six Months Ended June 30, 2023
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	24	%	—	%	—	%	24	%	25	%	—	%	—	%	25	%
Patients	10	%	—	%	—	%	10	%	10	%	—	%	—	%	10	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%
Third party	36	%	—	%	—	%	36	%	35	%	—	%	—	%	35	%
Total Dx revenues by payer	78	%	—	%	—	%	78	%	78	%	—	%	—	%	78	%
BLS
Pharmaceutical, biotechnology, and medical device companies	9	%	9	%	4	%	22	%	9	%	9	%	4	%	22	%
Total revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%

Revenues in the U.S. were $2,698.8 (83.8%) and $2,537.0 (83.6%) for the three months ended June 30, 2024 and 2023, respectively, and were $5,353.4 (83.7%) and $5,094.4 (83.9%) for the six months ended June 30, 2024 and 2023, respectively.